Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications

See-Hyoung Park; Kyu Yun Jang; Min Jae Kim; Sarah Yoon; Yuna Jo; So Mee Kwon; Kyoung Min Kim; Keun Sang Kwon; Chan Young Kim; Hyun Goo Woo

doi:10.18632/oncotarget.6264

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications

See-Hyoung Park, Kyu Yun Jang, Min Jae Kim, Sarah Yoon, Yuna Jo, So Mee Kwon, Kyoung Min Kim, Keun Sang Kwon, Chan Young Kim and Hyun Goo Woo _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:44819-44831. https://doi.org/10.18632/oncotarget.6264

Metrics: PDF 1921 views | HTML 2577 views | ?

Abstract

See-Hyoung Park1,2,*, Kyu Yun Jang4,*, Min Jae Kim1,3,*, Sarah Yoon1, Yuna Jo1,3, So Mee Kwon1,3, Kyoung Min Kim4, Keun Sang Kwon5, Chan Young Kim6, Hyun Goo Woo1,3

1Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea

2Program in Nano Science and Technology, Department of Transdisciplinary Studies, Seoul National University Graduate School of Convergence Science and Technology, Suwon, Republic of Korea

3Department of Biomedical Sciences, Graduate School, Ajou University, Suwon, Republic of Korea

4Department of Pathology, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital and Research Institute for Endocrine Sciences, Jeonju, Republic of Korea

5Department of Preventive Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea

6Department of Surgery, Chonbuk National University Medical School, Jeonju, Republic of Korea

*These authors have contributed equally to this work

Correspondence to:

Hyun Goo Woo, e-mail: [email protected]

Keywords: olaparib, PARP1, FOXO3A, prognosis, G2/M arrest

Received: May 27, 2015 Accepted: October 22, 2015 Published: November 02, 2015

ABSTRACT

Poly (ADP-ribose) polymerase1 (PARP1) has been reported as a possible target for chemotherapy in many cancer types. However, its action mechanisms and clinical implications for gastric cancer survival are not yet fully understood. Here, we investigated the effect of PARP1 inhibition in the growth of gastric cancer cells. PARP1 inhibition by Olaparib or PARP1 siRNA could significantly attenuate growth and colony formation of gastric cancer cells, and which were mediated through induction of G2/M cell cycle arrest but not apoptosis. FOXO3A expression was induced by PARP1 inhibition, suggesting that FOXO3A might be one of downstream target of the PARP1 effect on gastric cancer cell growth. In addition, by performing tissue microarrays on the 166 cases of gastric cancer patients, we could observe that the expression status of PARP1 and FOXO3A were significantly associated with overall survival (OS) and relapse-free survival (RFS). Strikingly, combined expression status of PARP1 and FOXO3A showed better prediction for patient’s clinical outcomes. The patient group with PARP1+/FOXO3A− expression had the worst prognosis while the patient group with PARP1−/FOXO3A+ had the most favorable prognosis (OS: P = 6.0 × 10⁻⁹, RFS: P = 2.2 × 10⁻⁸). In conclusion, we suggest that PARP1 and FOXO3A play critical roles in gastric cancer progression, and might have therapeutic and/or diagnostic potential in clinic.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6264

Publication Alerts

Research Papers:

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications

Abstract